A method of combating movement disorder in a patient experiencing or susceptible to same, by administering to the patient an effective amount of a neurotransmission modulating composition including a 5HT antagonist and/or alpha 2 antagonist. The antagonist may for example include a piperazinoazepine compound such as mirtazapine that is a receptor antagonist for 5HT2/3 and alpha 2 receptors.
TREATMENT OF MOVEMENT DISORDERS BY ADMINISTRATION OF 5-HYDROXYTRYPTAMINE RECEPTOR/$g(a) 2? ADRENERGIC RECEPTOR ANTAGONIST COMPOSITIONS